Latest News | AstraZeneca Gets CDSCO Nod for Cancer Drug

New Delhi, Jun 1 (PTI) AstraZeneca Pharma India on Thursday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) for its cancer drug Tremelimumab Concentrate to be administered intravenously.

The approval for Tremelimumab in combination with Durvalumab is based on results from Phase III HIMALAYA clinical trial and is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC), the drug firm said.

Also Read | Hydrogen-Powered Toyota Corolla Race Car Introduced As Auto Racing Makes Its Shift Away From Fossil Fuel Guzzlers.

The trial was conducted in 181 centres across 16 countries, including in the US, Canada, Europe, South America and Asia including India, it added.

The approval paves the way for the launch of Tremelimumab solution of 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single-dose vials in India for the specified indication, AstraZeneca Pharma said.

Also Read | Greenland Glaciers and Ice Caps Are Melting Three Times Faster Than 20th Century, Finds Concerning Study.

"This approval is in line with our ambition of transforming patient outcomes and not leaving any patient behind. We have a breadth of scientific platforms to attack cancer while exploring the power of combinations, seeking to drive deeper and more durable responses," AstraZeneca India Country President and Managing Director Sanjeev Panchal noted.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)